|
| Scoring systems |
| Study | Factors | Equation | Method | Risk categories | Target prediction | Data and results |
|
| Sokal score, Sokal et al. [17] | Age, spleen size (cm), blast (%), and platelets (109/L) | exp(0.0116 × (age [years] − 43.4)) + 0.0345 × (spleen size [cm] − 7.51) + (0.188 × ((platelets [109/L]/700)2 − 0.563)) + (0.0887 × (blasts [%] − 2.10)) | Multivariate analysis of survival | Low-risk score < 0.8, of patients, intermediate-risk in 0.8–1.2, and high-risk > 1.2 | Risk groups for chemotherapy | Six European and American sources (), low 39%, intermediate 38%, and high 23% |
|
| Hasford score, Hasford et al. [14] | Age, spleen size (cm), blasts (%), eosinophils (%), basophils (%), and platelets (109/L) | (0.6666 × age [0 when age < 50 years; 1 otherwise]) + (0.0420 × spleen size [cm]) + (0.0584 × blasts [%]) + (0.0413 × eosinophils [%]) + (0.2039 × basophils [0 when basophils < 3%; 1 otherwise]) + (1.0956 × platelet count [0 when platelets < 1500 × 109/L; 1 otherwise]) × 1000 | Multivariate analysis of survival | Low-risk score ≤ 780, intermediate-risk in 781–1480, and high-risk ≥ 1481 | Risk groups for interferon alpha alone | 14 studies (), low 40.6%, intermediate 44.7%, and high 14.6% |
|
| EUTOS score, Hasford et al. [15] | Basophils (%) and spleen size (cm) | (7 × basophil [%]) + (4 × spleen [cm]) | Multivariate analysis of response | Low-risk score < 87 and high-risk ≥ 87 | CCgR at 18 months to imatinib | Five national study groups (,060), low 79% and high 21% |
|
| ELTS score, Pfirrmann et al. [18] | Age, spleen size (cm), blast (%), and platelets (109/L) | 0.0025 × (age in completed years/10)3 + 0.0615 × spleen size below costal margin + 0.1052 × blasts in peripheral blood + 0.4104 × (platelet count/1000)−0.5 | Multivariate analysis of response | Low-risk score ≤ 1.5680, intermediate-risk in 1.5680–2.2185, and high-risk > 2.2185 | Long-term survival | (,205), low 61%, intermediate 27%, and high 12% |
|
